A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

Patients with T4N+ or T1-3N2 disease will be randomly assigned to either the control group (FOLFOX/CAPOX for 6 months) or the intervention group (FOLFOX/CAPOX plus bevacizumab for 6 months) to receive adjuvant therapy. Venous blood samples (8-16 mL) will be collected at 1 month, 3 months, and 6 months postoperatively for dynamic monitoring of plasma ctDNA.

Trial Details

NCT ID
NCT07562490
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Rectal Cancer Colorectal Cancer
Interventions
  • FOLFOX
  • Folfox plus Bevacizumab
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥18 years, regardless of sex;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of \>3 months;
  • Histologically confirmed postoperative pTNM stage high-risk stage II colorectal cancer;
  • Positive ctDNA status at 1 month after surgery;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Rectal Cancer Colorectal Cancer Trials on Trialify →